Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.
Recruiting now · Phase 2
Conditions studied: Colorectal Cancer
In brief
All patients with locally advanced colorectal cancer after radical surgical intervention who have not previously received systemic antitumor treatment will be randomized into two groups receiving fluoropyrimidines in mono-regimen and in combination with oxaliplatin. Main objectives: * to compare the 3-year disease-free survival and 5-year overall survival rates in the two groups. * to identify, through a comprehensive geriatric assessment among elderly patients, the groups that benefit most from adjuvant chemotherapy. Patients will be treated until progression of the process is detected or the maximum effect of therapy is reached (the longest duration of treatment is 6 months).
Key facts
- Study ID
- NCT06888843
- Run by
- Nizhny Novgorod Regional Clinical Oncology Center
- People needed
- 160
- Starts
- 2025-02-01
- Expected to finish
- 2028-02-01
- Last updated by the study team
- 2025-03-27
Who can join
Age: 70 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 70 years and older;
- Obtaining informed consent to participate in the study;
- Morphologically confirmed diagnosis of colorectal cancer;
- Stage III colorectal cancer;
- Underwent radical surgical intervention for primary colorectal tumor;
- ECOG score of 0 - I;
- Life expectancy of more than 6 months;
- No history of systemic drug therapy for CRC;
- Adequate liver, kidney and bone marrow function;
- Absence of severe uncontrolled concomitant chronic diseases and acute illnesses.
You may not qualify if…
- Having previously received any systemic therapy for CRC;
- Time after surgical treatment of more than 12 weeks;
- Stage I-II and IV disease;
- Confirmed dihydropyrimidine dehydrogenase deficiency in blood by PCR (alteration of alleles c.[190511G > A], c.[1679T >G],[2846A > T], [1129-5923C >G], [c.1236 G>A(HapB3)]);
- Severe uncontrolled comorbid chronic diseases or acute illnesses;
- Presence of a second malignancy (except for previously cured malignancies);
- Any condition that, in the opinion of the physician, would interfere with the study procedures.
Where it is running
- Research Institute of Clinical Oncology "Nizhny Novgorod Regional Clinical Oncological Dispensary" — Nizhny Novgorod, Russia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.